JPH0261481B2 - - Google Patents
Info
- Publication number
- JPH0261481B2 JPH0261481B2 JP56065892A JP6589281A JPH0261481B2 JP H0261481 B2 JPH0261481 B2 JP H0261481B2 JP 56065892 A JP56065892 A JP 56065892A JP 6589281 A JP6589281 A JP 6589281A JP H0261481 B2 JPH0261481 B2 JP H0261481B2
- Authority
- JP
- Japan
- Prior art keywords
- water
- reaction
- cells
- polysaccharide
- miscible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 238000006243 chemical reaction Methods 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 150000004676 glycans Chemical class 0.000 claims description 32
- 229920001282 polysaccharide Polymers 0.000 claims description 32
- 239000005017 polysaccharide Substances 0.000 claims description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 239000002244 precipitate Substances 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- 241000893536 Epimedium Species 0.000 claims description 13
- 235000018905 epimedium Nutrition 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 238000000862 absorption spectrum Methods 0.000 claims description 8
- 239000006286 aqueous extract Substances 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 6
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000002523 gelfiltration Methods 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 claims description 3
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 3
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 3
- 229940074386 skatole Drugs 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 2
- 239000012507 Sephadex™ Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical class CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 238000000921 elemental analysis Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 238000005199 ultracentrifugation Methods 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 56
- 239000000284 extract Substances 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 21
- 239000012980 RPMI-1640 medium Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 206010057249 Phagocytosis Diseases 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000008782 phagocytosis Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 8
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000003399 chemotactic effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- -1 acetone Chemical compound 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 238000002738 Giemsa staining Methods 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000004816 paper chromatography Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000893531 Epimedium koreanum Species 0.000 description 1
- 241001362411 Epimedium sagittatum Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- POIRVLZGTSWEMG-UHFFFAOYSA-N Magnoflorin Natural products N1CCC2=CC(OC)=C(O)C3=C2C1CC1=CC=C(OC)C(O)=C13 POIRVLZGTSWEMG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920008262 Thermoplastic starch Polymers 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical class CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- OGYXOOJUJQIDOX-UHFFFAOYSA-N epimedoside A Natural products OC1C(O)C(O)C(C)OC1OC1=C(C=2C=CC(O)=CC=2)OC2=C(CC=C(C)C)C(OC3C(C(O)C(O)C(CO)O3)O)=CC(O)=C2C1=O OGYXOOJUJQIDOX-UHFFFAOYSA-N 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56065892A JPS57181017A (en) | 1981-04-30 | 1981-04-30 | Polysaccharide ps-a from plant of genus epimedium, its preparation, and immune enhancer comprising polysaccharide ps-a as active ingredient |
| US06/456,027 US4528188A (en) | 1981-04-30 | 1982-04-20 | Polysaccharide PS-A obtained from barrenwort deriving from plants belonging to the genus Epimedium, process for preparation thereof and phylactic and immunostimulating agents comprising said polysaccharide PS-A effective component |
| DE19823242672 DE3242672T1 (de) | 1981-04-30 | 1982-04-20 | Polysaccharide ps-a erhalten von pflanzen, die zur gattung epimedium gehoeren, verfahren zu deren herstellung und phylactische und immunostimulierende mittel, welche dieses polysaccharid ps-a als wirksame komponente enthalten |
| AU83346/82A AU8334682A (en) | 1981-04-30 | 1982-04-20 | Polysaccharide ps=a isolated from the plant of genus epimedium violaceium morr. et decne., process for its preparation, and infection-preventing agent and immunostimulating agent containing the ploysaccharide as effective ingredient |
| GB838314489A GB8314489D0 (en) | 1981-04-30 | 1982-04-20 | Polysaccharide ps-a |
| PCT/JP1982/000132 WO1982003771A1 (fr) | 1981-04-30 | 1982-04-20 | Polysaccharide ps-a isole a partir de la plante appartenant au genre epidemium violaceum morr. et decne., procede de preparation, et agent de prevention de l'infection et stimulateur de l'immunite contenant le polysaccharide a titre d'ingredient efficace |
| EP82901157A EP0086233A1 (en) | 1981-04-30 | 1982-04-20 | Polysaccharide ps-a isolated from the plant of genus epimedium violaceum morr. et decne., process for its preparation, and infection-preventing agent and immunostimulating agent containing the polysaccharide as effective ingredient |
| CA000401970A CA1188687A (en) | 1981-04-30 | 1982-04-29 | Polysaccharide ps-a obtained from plants of genus epimedium sp., process for preparation thereof and phylactic and immunostimulating agents comprising said polysaccharide ps-a as effective component |
| IT2100782A IT1209459B (it) | 1981-04-30 | 1982-04-29 | Agente filattico o profilattico e immunostimolante costituito da un polisaccaride. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56065892A JPS57181017A (en) | 1981-04-30 | 1981-04-30 | Polysaccharide ps-a from plant of genus epimedium, its preparation, and immune enhancer comprising polysaccharide ps-a as active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57181017A JPS57181017A (en) | 1982-11-08 |
| JPH0261481B2 true JPH0261481B2 (enrdf_load_stackoverflow) | 1990-12-20 |
Family
ID=13300060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56065892A Granted JPS57181017A (en) | 1981-04-30 | 1981-04-30 | Polysaccharide ps-a from plant of genus epimedium, its preparation, and immune enhancer comprising polysaccharide ps-a as active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57181017A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6034293B2 (ja) * | 2010-11-05 | 2016-11-30 | ベイジン チョンアン アジュバント バイオテクノロジー カンパニー，リミティド | イカリソウの多糖、その画分、及びワクチンアジュバントとしてのその使用 |
-
1981
- 1981-04-30 JP JP56065892A patent/JPS57181017A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57181017A (en) | 1982-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0247071B1 (en) | Immunotherapeutic treatment | |
| US4843067A (en) | Polysaccharide containing pharmaceutical composition for increasing the immune function | |
| Davies | The isolation of mouse antigens carrying H2-histocompatibility specificity: some preliminary studies | |
| FI59024C (fi) | Foerfarande foer framstaellning och rening av en antigen till c-gruppen hoerande meningokockpolysackarid som har hoeg molekylvikt och aer aktiv mot av c-gruppens meningokocker orsakad meningit | |
| CA1093963A (fr) | Procede de preparation de nouveaux polysaccharides extraits de corps microbiens d'haemophilus influenzae | |
| EP0008969A2 (en) | Vaccine and method of making | |
| US3148120A (en) | Hot aqueous phenol extraction of gramnegative bacterial lipopolysaccharides | |
| EP0041897A2 (en) | Polysaccharide antigen from streptococcus and vaccines | |
| US4528188A (en) | Polysaccharide PS-A obtained from barrenwort deriving from plants belonging to the genus Epimedium, process for preparation thereof and phylactic and immunostimulating agents comprising said polysaccharide PS-A effective component | |
| US4944946A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| JPH0261481B2 (enrdf_load_stackoverflow) | ||
| US4501736A (en) | Extract from barrenwort | |
| JPH0144719B2 (enrdf_load_stackoverflow) | ||
| US4235994A (en) | High molecular weight meningococcal group C vaccine and method for preparation thereof | |
| US4985247A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| KR20010040752A (ko) | 에이즈 치료제 | |
| Kligler et al. | The antigenic composition of Trypanosoma evansi | |
| JPS63119427A (ja) | 抗アレルギ−剤 | |
| US3267090A (en) | Viscumic acid and salts thereof | |
| JPS61167620A (ja) | 多糖類を含んで成る抗癌剤 | |
| US4944945A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| JPH10158184A (ja) | 細胞接着抑制剤 | |
| Ross | THE RÔLE OF THE SOLUBLE SPECIFIC SUBSTANCE IN ORAL IMMUNIZATION AGAINST PNEUMOCOCCUS TYPE I | |
| JPH10120576A (ja) | Ｈｓｐ６０ファミリーに属するタンパク質のアロイン誘導体含有合成抑制剤 | |
| JPS601877B2 (ja) | 高分子多糖類物質ｍｐｓ−８０及びその製造法 |